The Finnish Formula: Finding Balance and Building Innovation with Dr. Antti Vuolanto
In this episode of Clinical Trialblazers, Dr. Antti Vuolanto, CEO of Herantis Pharma Plc, shares his unconventional journey into the biotech industry, from bioengineering to leading a company focused on central nervous system (CNS) diseases. He discusses the scientific innovation behind HER096, a potential game-changer for Parkinson's disease, and the challenges of drug development. Beyond the science, Dr. Vuolanto offers profound lessons on the importance of building trust with colleagues and investors, the importance of taking risks, and the importance of work-life balance (a Finnish secret to happiness!). This episode highlights the power of mentorship, honest communication, and a deep commitment to impacting patients’ lives. He discusses the importance of mentorship, the challenges of drug development, and the significance of building trust with investors.
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026